Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Return on Capital Employed (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Return on Capital Employed for 11 consecutive years, with 1.0% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed fell 118.0% to 1.0% in Q3 2025 year-over-year; TTM through Sep 2025 was 1.0%, a 118.0% decrease, with the full-year FY2024 number at 0.69%, down 56.0% from a year prior.
  • Return on Capital Employed was 1.0% for Q3 2025 at Marker Therapeutics, up from 1.3% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.18% in Q3 2024 to a low of 1.3% in Q2 2025.
  • A 5-year average of 0.6% and a median of 0.7% in 2022 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: skyrocketed 100bps in 2024, then plummeted -136bps in 2025.
  • Marker Therapeutics' Return on Capital Employed stood at 0.69% in 2021, then fell by -1bps to 0.7% in 2022, then soared by 72bps to 0.19% in 2023, then tumbled by -342bps to 0.86% in 2024, then decreased by -17bps to 1.0% in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Return on Capital Employed are 1.0% (Q3 2025), 1.3% (Q2 2025), and 0.77% (Q1 2025).